Article in American journal of respiratory cell and molecular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 2 institutions in 1 country.
Sreelakshmi VasudevanMedical Service, San Francisco Veterans Affairs Healthcare System, San Francisco, California.
Joshua J VásquezDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine.ORCID 0000-0002-7165-5739
Wenxuan ChenMedical Service, San Francisco Veterans Affairs Healthcare System, San Francisco, California.
Brandon Aguilar-RodriguezDivision of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Erene C NiemiMedical Service, San Francisco Veterans Affairs Healthcare System, San Francisco, California.
Siyang ZengMedical Service, San Francisco Veterans Affairs Healthcare System, San Francisco, California.
Whitney TamakiDivision of Experimental Medicine.
Mary C NakamuraMedical Service, San Francisco Veterans Affairs Healthcare System, San Francisco, California.
Mehrdad ArjomandiMedical Service, San Francisco Veterans Affairs Healthcare System, San Francisco, California.ORCID 0000-0002-0116-9217
San Francisco VA Medical Center · USSan Francisco General Hospital · US
Funding
Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PALMER, SARAH ELIZABETH · 2011 to 2015
$29.5M
Delaney AIDS Research Enterprise to Cure HIVUM1AI126611 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT, PICKER, LOUIS J. · 2016 to 2020
$27.9M
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VAISSE, CHRISTIAN · 2003 to 2019
$21.8M
RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2M
Innate immune regulation of stem cells in bone formationR01AR066735 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSIAO, EDWARD C · 2015 to 2019
$1.8M
Host and microbial factors promoting synergistic mortality during polymicrobial intra-abdominal infections with Candida albicans and Staphylococcus aureusR01AI116025 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI NOVERR, MAIRI C · 2015 to 2019
$1.8M
Targeting latent HIV-1 Reservoirs with the Antibody-Drug Conjugate, Brentuximab VedotinR33AI116205 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2016 to 2018
$1.2M
The impact of the HIV reservoir on pulmonary myeloid cells: virology, phenotype, and functionK01HL140804 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VASQUEZ, JOSHUA · 2019 to 2023
$956k
UCSF DVS CyTOF Mass CytometerS10OD018040 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LANIER, LEWIS LEE · 2014 to 2014
Lung myeloid cells are important in pulmonary immune homeostasis and in the pathogenesis of chronic obstructive pulmonary disease (COPD). Multiparameter immunophenotypic characterization of these cells is challenging because of their autofluorescence and diversity. We evaluated the immunophenotypic landscape of airway myeloid cells in COPD using time of flight mass cytometry. Cells from BAL, which were obtained from never-smokers (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Lower PDL1, PDL2, and AXL Expression on Lung Myeloid Cells Suggests Inflammatory Bias in Smoking and Chronic Obstructive Pulmonary Disease. · full record | OpenQuestion